Clinical potential of lurasidone in the management of schizophrenia
Ludovic Samalin, Marion Garnier, Pierre-Michel LlorcaCentre Hospitalier Universitaire, Clermont-Ferrand, FranceAbstract: Lurasidone is a new second-generation antipsychotic approved in October 2010 by the Food and Drug Administration for the treatment of schizophrenia. Like other second-generation a...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2011-06-01
|
| Series: | Therapeutics and Clinical Risk Management |
| Online Access: | http://www.dovepress.com/clinical-potential-of-lurasidone-in-the-management-of-schizophrenia-a7743 |